LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 106

Search options

  1. Article ; Online: Disparities in Maternal and Infant Outcomes: What's a Neurologist to Do?

    Langer-Gould, Annette / Igbinosa, Irogue I

    Neurology

    2024  Volume 102, Issue 4, Page(s) e209207

    MeSH term(s) Humans ; Infant ; Health Status Disparities ; Maternal Health ; Infant Health
    Language English
    Publishing date 2024-01-23
    Publishing country United States
    Document type Editorial
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000209207
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Traumatic brain injury, race, ethnicity and cognition in newly diagnosed persons with multiple sclerosis.

    Akinsanya, Jemima / Smith, Jessica B / Langer-Gould, Annette

    Multiple sclerosis and related disorders

    2024  Volume 86, Page(s) 105577

    Abstract: We sought to determine whether a history of traumatic brain injury (TBI) could explain the lower symbol digit modalities test (SDMT) scores observed among newly diagnosed multiple sclerosis (MS) and control participants identifying as Black or Hispanic ... ...

    Abstract We sought to determine whether a history of traumatic brain injury (TBI) could explain the lower symbol digit modalities test (SDMT) scores observed among newly diagnosed multiple sclerosis (MS) and control participants identifying as Black or Hispanic versus white in the MS Sunshine Study (n = 1172). 330 (29.2 %) participants reported a history of ≥1 TBI. Accounting for TBI did not explain the significant independent associations between having MS, being Black or Hispanic and lower SDMT. The pervasive effects of systemic racism in the United States remain the best explanation for the lower SDMT scores observed in Black and Hispanic participants.
    Language English
    Publishing date 2024-03-25
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2024.105577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Treating severe MS relapses during pregnancy.

    Langer-Gould, Annette

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2021  Volume 27, Issue 10, Page(s) 1623–1624

    MeSH term(s) Chronic Disease ; Female ; Humans ; Pregnancy ; Recurrence
    Language English
    Publishing date 2021-04-30
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585211012206
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reader Response: Leadership, Recognition Awards, and Publication by Men and Women in the American Academy of Neurology.

    Langer-Gould, Annette

    Neurology

    2021  Volume 97, Issue 4, Page(s) 200–201

    MeSH term(s) Academies and Institutes ; Awards and Prizes ; Female ; Humans ; Leadership ; Male ; Neurology ; United States
    Language English
    Publishing date 2021-07-26
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000012333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.

    Langer-Gould, Annette / Li, Bonnie H / Smith, Jessica B / Xu, Stanley

    Neurology(R) neuroimmunology & neuroinflammation

    2024  Volume 11, Issue 3, Page(s) e200211

    Abstract: Background and objectives: B-cell-depleting therapies increase the risk of infections and hypogammaglobulinemia. These relationships are poorly understood. The objectives of these analyses were to estimate how much of this rituximab-associated infection ...

    Abstract Background and objectives: B-cell-depleting therapies increase the risk of infections and hypogammaglobulinemia. These relationships are poorly understood. The objectives of these analyses were to estimate how much of this rituximab-associated infection risk is mediated by hypogammaglobulinemia and to identify other modifiable risk factors in persons with multiple sclerosis (pwMS).
    Methods: We conducted a retrospective cohort study of rituximab-treated pwMS from January 1, 2008, to December 31, 2020, in Kaiser Permanente Southern California. Cumulative rituximab dose was defined as ≤2, >2 and ≤4, or >4 g. Serious infections were defined as infections requiring or prolonging hospitalizations, and recurrent outpatient infections as seeking care for ≥3 within 12 months. Exposures, outcomes, and covariates were collected from the electronic health record. Adjusted hazard ratios (aHRs) were estimated using Andersen-Gill hazards models, and generalized estimating equations were used to examine correlates of IgG values. Cross-sectional causal mediation analyses of rituximab and hypogammaglobulinemia were conducted.
    Results: We identified 2,482 pwMS who were treated with rituximab for a median of 2.4 years (interquartile range = 1.3-3.9). The average age at rituximab initiation was 43.0 years, 71.9% were female, 49.7% were White, non-Hispanic patients, and 29.6% had advanced disability (requiring walker or worse). Seven hundred patients (28.2%) developed recurrent outpatient infections, 155 (6.2%) developed serious infections, and only 248 (10.0%) had immunoglobulin G (IgG) < 700 mg/dL. Higher cumulative rituximab dose (>4 g) was correlated with lower IgG levels (Beta = -58.8,
    Discussion: Higher cumulative rituximab doses increase the risk of infections even in this population where 90% of patients maintained normal IgG levels. Clinicians should strive to use minimally effective doses of rituximab and other B-cell-depleting therapies and consider important comorbidities to minimize risks of infections.
    MeSH term(s) Humans ; Female ; Male ; Rituximab/adverse effects ; Agammaglobulinemia/chemically induced ; Agammaglobulinemia/epidemiology ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/complications ; Retrospective Studies ; Cross-Sectional Studies ; Immunoglobulin G ; Infections/chemically induced ; Infections/epidemiology
    Chemical Substances Rituximab (4F4X42SYQ6) ; Immunoglobulin G
    Language English
    Publishing date 2024-03-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2767740-0
    ISSN 2332-7812 ; 2332-7812
    ISSN (online) 2332-7812
    ISSN 2332-7812
    DOI 10.1212/NXI.0000000000200211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Rituximab for Multiple Sclerosis: Hiding in Plain Sight

    Langer-Gould, Annette / Sotirchos, Elias S / Bourdette, Dennis

    Neurology

    2023  Volume 102, Issue 2, Page(s) e208063

    Abstract: In February 2023, following extensive discussions with stakeholders and data review, the Institute for Clinical and Economic Review issued final policy recommendations for treatment of relapsing multiple sclerosis (RMS) ...

    Abstract In February 2023, following extensive discussions with stakeholders and data review, the Institute for Clinical and Economic Review issued final policy recommendations for treatment of relapsing multiple sclerosis (RMS)
    MeSH term(s) United States ; Humans ; Biosimilar Pharmaceuticals/therapeutic use ; Multiple Sclerosis/drug therapy ; Rituximab/therapeutic use ; Academies and Institutes ; Drugs, Essential
    Chemical Substances Biosimilar Pharmaceuticals ; Rituximab (4F4X42SYQ6) ; Drugs, Essential
    Language English
    Publishing date 2023-12-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000208063
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Editorial Response to Drs. Simone and Mancusi.

    Langer-Gould, Annette

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2020  Volume 101, Page(s) 367

    MeSH term(s) Anti-Inflammatory Agents ; COVID-19 ; Humans ; SARS-CoV-2
    Chemical Substances Anti-Inflammatory Agents
    Keywords covid19
    Language English
    Publishing date 2020-10-02
    Publishing country Canada
    Document type Letter ; Comment
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2020.09.1455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Open Access Fees: A Barrier to Scholarly Activity Among Neurology Trainees.

    Lam, Keng / Langer-Gould, Annette

    The Permanente journal

    2021  Volume 25

    Abstract: The open access publishing model provides readers of all backgrounds access to articles free of charge. To cover the costs of open access, however, many journals now charge substantial article processing fees. This has inadvertently created yet another ... ...

    Abstract The open access publishing model provides readers of all backgrounds access to articles free of charge. To cover the costs of open access, however, many journals now charge substantial article processing fees. This has inadvertently created yet another barrier for trainees to engage in scholarly activity. Herein, we describe the issue, review the literature, and provide suggestions for addressing this barrier with the focus on the neurology specialty.
    MeSH term(s) Access to Information ; Bibliometrics ; Humans ; Neurology
    Language English
    Publishing date 2021-11-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2062823-7
    ISSN 1552-5775 ; 1552-5775
    ISSN (online) 1552-5775
    ISSN 1552-5775
    DOI 10.7812/TPP/21.041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The Role of Diet in Multiple Sclerosis: Food for Thought.

    Spain, Rebecca I / Piccio, Laura / Langer-Gould, Annette M

    Neurology

    2022  Volume 100, Issue 4, Page(s) 167–168

    MeSH term(s) Humans ; Multiple Sclerosis/etiology ; Diet ; Food
    Language English
    Publishing date 2022-10-18
    Publishing country United States
    Document type Editorial
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000201565
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Pregnancy and Family Planning in Multiple Sclerosis.

    Langer-Gould, Annette M

    Continuum (Minneapolis, Minn.)

    2019  Volume 25, Issue 3, Page(s) 773–792

    Abstract: Purpose of review: This article provides practical guidance on successful management of women with multiple sclerosis (MS) through pregnancy and the postpartum period.: Recent findings: Recent studies indicate that most women diagnosed with MS today ... ...

    Abstract Purpose of review: This article provides practical guidance on successful management of women with multiple sclerosis (MS) through pregnancy and the postpartum period.
    Recent findings: Recent studies indicate that most women diagnosed with MS today can have children, breast-feed, and resume beta interferons or glatiramer acetate per their preferences without incurring an increased risk of relapses during the postpartum period. More than 40% of women with mild MS do not require any treatment before conception or in the postpartum period. Women with highly active MS can now become well-controlled before, throughout, and after pregnancy via highly effective treatments. Unfortunately, pregnancy does not protect against relapses following the cessation of fingolimod or natalizumab, and some women experience severe rebound relapses during pregnancy. Accidental first-trimester exposure to teriflunomide or fingolimod increases the risk of fetal harm.
    Summary: Most women with MS can have normal pregnancies and breast-feed without incurring harm. Clinicians should avoid prescribing medications with known teratogenic potential (teriflunomide, fingolimod), known risk of severe rebound relapses (fingolimod, natalizumab), or unclear but plausible risks (dimethyl fumarate, alemtuzumab) to women of childbearing age who desire pregnancy or are not on reliable birth control. If a treatment needs to be resumed during breast-feeding, clinicians should opt for glatiramer acetate, interferon beta, natalizumab, or rituximab/ocrelizumab, as biologically plausible risks to the infant are exceedingly low.
    MeSH term(s) Adult ; Breast Feeding/trends ; Family Planning Services/trends ; Female ; Glatiramer Acetate/administration & dosage ; Humans ; Immunologic Factors/administration & dosage ; Interferon-beta/administration & dosage ; Multiple Sclerosis/diagnostic imaging ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab/administration & dosage ; Pregnancy ; Pregnancy Complications/diagnostic imaging ; Pregnancy Complications/drug therapy ; Young Adult
    Chemical Substances Immunologic Factors ; Natalizumab ; Glatiramer Acetate (5M691HL4BO) ; Interferon-beta (77238-31-4)
    Language English
    Publishing date 2019-06-20
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ISSN 1538-6899
    ISSN (online) 1538-6899
    DOI 10.1212/CON.0000000000000745
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top